83,000 Shares in Novo Nordisk A/S (NVO) Acquired by Tekla Capital Management LLC

Tekla Capital Management LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 83,000 shares of the company’s stock, valued at approximately $2,845,000.

Other large investors have also recently made changes to their positions in the company. Polen Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 12.2% in the fourth quarter. Polen Capital Management LLC now owns 15,766 shares of the company’s stock valued at $565,000 after buying an additional 1,716 shares during the period. Elkfork Partners LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $516,000. Marshall Wace LLP increased its stake in shares of Novo Nordisk A/S by 122.5% in the fourth quarter. Marshall Wace LLP now owns 396,724 shares of the company’s stock valued at $14,227,000 after buying an additional 218,420 shares during the period. Frontier Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $592,000. Finally, Glenview Trust Co purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $243,000. Institutional investors own 6.34% of the company’s stock.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE NVO) traded down 1.17% on Tuesday, reaching $43.17. 1,473,089 shares of the company’s stock were exchanged. The company has a market capitalization of $107.74 billion, a P/E ratio of 18.74 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $57.41. The firm has a 50-day moving average price of $41.74 and a 200-day moving average price of $36.89.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/06/20/tekla-capital-management-llc-invests-2-85-million-in-novo-nordisk-as-nvo-updated.html.

Several research firms have recently commented on NVO. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, March 8th. TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. BidaskClub upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, June 15th. Barclays PLC started coverage on shares of Novo Nordisk A/S in a report on Tuesday, March 7th. They set an “underweight” rating for the company. Finally, HSBC Holdings plc cut shares of Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus target price of $57.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply